Ultragenyx Pharma (RARE) is Initiated by Canaccord Genuity to Buy according to the research report released to the investors. The brokerage firm has set the Price Target of the shares at $126. The shares recommendation by the Brokerage Firm was released on Dec-22-2015.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) ended Thursday session in red amid volatile trading. The shares closed down 1.06 points or 0.95% at $110.37 with 281,710 shares getting traded. Post opening the session at $112, the shares hit an intraday low of $107.99 and an intraday high of $113.15 and the price vacillated in this range throughout the day. The company has a market cap of $4,286 million and the number of outstanding shares has been calculated to be 38,834,703 shares. The 52-week high of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is $137.05 and the 52-week low is $39.46.
During the last several months other analysts have commented on the company rating. Stifel Nicolaus initiates coverage on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). The shares have now been rated Buy by the stock experts at the ratings house. The rating by the firm was issued on December 1, 2015.
Research firm Zacks has rated Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and has ranked it at 3, indicating that for the short term the shares are a hold. 9 Wall Street analysts have given the company an average rating of 1.33. The shares has received a hold rating based on the suggestion from 1 analysts in latest recommendations. Strong buy was given by 7 Wall Street Analysts. The company had a buy rating from 1 analysts.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares are expected to touch $120.88 in the short term. This short term price target has been shared by 8 analysts. However, the standard deviation of short term price estimate has been valued at 2.8. The target price could hit $125 on the higher end and $118 on the lower end.
Shares of Ultragenyx Pharmaceutical Inc. rose by 9.5% in the last five trading days and 10.44% for the last 4 weeks. Ultragenyx Pharmaceutical Inc. has dropped 15.04% during the last 3-month period . Year-to-Date the stock performance stands at 151.53%.
Ultragenyx Pharmaceutical Inc. is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company focuses on diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. The Company’s pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. The Company’s product include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM.